Abstract: The modern treatment of cardiac arrest is an increasingly complex medical procedure with a rapidly changing array of therapeutic approaches designed to restore life to victims of sudden death. The 2 primary goals of providing artificial circulation and defibrillation to halt ventricular fibrillation remain of paramount importance for saving lives. They have undergone significant improvements in technology and dissemination into the community subsequent to their establishment 60 years ago. The evolution of artificial circulation includes efforts to optimize manual cardiopulmonary resuscitation, external mechanical cardiopulmonary resuscitation devices designed to augment circulation, and may soon advance further into the rapid deployment of specially designed internal emergency cardiopulmonary bypass devices. The development of defibrillation technologies has progressed from bulky internal defibrillators paddles applied directly to the heart, to manually controlled external defibrillators, to automatic external defibrillators that can now be obtained over-the-counter for widespread use in the community or home. But the modern treatment of cardiac arrest now involves more than merely providing circulation and defibrillation. As suggested by a 3-phase model of treatment, newer approaches targeting patients who have had a more prolonged cardiac arrest include treatment of the metabolic phase of cardiac arrest with therapeutic hypothermia, agents to treat or prevent reperfusion injury, new strategies specifically focused on pulseless electric activity, which is the presenting rhythm in at least one third of cardiac arrests, and aggressive post resuscitation care. There are discoveries at the cellular and molecular level about ischemia and reperfusion pathobiology that may be translated into future new therapies. On the near horizon is the combination of advanced cardiopulmonary bypass plus a cocktail of multiple agents targeted at restoration of normal metabolism and prevention of reperfusion injury, as this holds the promise of restoring life to many patients for whom our current therapies fail. (Circ Res. 2015;116:2041-2049. DOI: 10.1161/CIRCRESAHA.116.304495.)

Key Words: heart arrest ■ reperfusion ■ resuscitation
Sudden cardiac arrest (SCA) is an important public health challenge. Despite a dramatic decrease in the age-adjusted risk of sudden cardiac death, the cumulative number of fatal SCA cases in the United States remains large. Estimates range from <170000 fatal SCA cases per year to >450000; a figure in the range of 300000 to 370000 per year is likely the best current estimate.\(^1\) SCA seems to account for \(\approx\)50% of all cardiovascular deaths,\(^2\) and it is estimated that 50% of the SCAs are the first clinical expression of previously undiagnosed heart disease.\(^3\) Most out-of-hospital cardiac arrests (80%) occur in private homes or other living facilities.\(^4\) Electric mechanisms associated with SCA are broadly classified into tachyarrhythmic and nontachyarrhythmic categories, the latter including pulseless electric activity (PEA, formerly referred to as electromechanical dissociation), asystole, extreme bradycardia, and other mechanisms, often associated with noncardiac factors. This article aims to review the cardiac rhythms associated with sudden death, the pathophysiology involved in cardiac resuscitation, and the current state of resuscitation science and techniques.

### Ventricular Fibrillation

In 2002, Weisfeldt proposed a 3-phase time-dependent model for treatment of cardiac arrest from ventricular fibrillation (VF) and pulseless ventricular tachycardia (VT) that remains at the forefront of our current treatment paradigm.\(^5\) The first or electric phase of cardiac arrest lasts for \(\approx\)5 minutes and is characterized by the need for rapid defibrillation as the top priority. Indeed survival rates for out of hospital cardiac arrest can exceed 60% for patients within this early electric phase. The second or circulatory phase of cardiac arrest lasts from \(\approx\)5 to 10 minutes after initiation of VF. It appears during this circulatory phase that the best therapy is to first give a brief period of vigorous chest compressions (between 100 and 300, the exact duration is not really known), followed by defibrillation. This implies that during this phase the immediate treatment of VF is not traditional defibrillation first, but rather chest compression first. The concept is that the initial vigorous chest compressions provide blood flow to the myocardi-um that improve the chances of successful defibrillation and long-term survival. This concept is not currently incorporated within the American Heart Association guidelines in part because it is not possible to know exactly which phase a person is in and it would make the teaching of advanced cardiac life support (ACLS) even more complicated. Weisfeldt also speculated on the existence of a third or metabolic phase of cardiac arrest that begins \(\approx\)10 minutes after the arrest. The treatment of patients who have remained without circulation for a prolonged cardiac arrest interval is difficult and in practice most deaths from cardiac arrest are from within this phase. During this metabolic phase, the model suggests that both compression and defibrillation are no longer sufficient therapies to routinely save lives of cardiac arrest victims. Metabolic resuscitation of some form is optimally required. It is during this phase that salvage therapies such as cardiopulmonary bypass plus metabolic drug combinations are required with components directed toward prevention and correction of reperfusion injury. A more detailed discussion of this metabolic phase and reperfusion injury is included in the second half of this article.

### Automatic External Defibrillators

The development of automatic external defibrillators (AEDs) has revolutionized out-of-hospital resuscitation. AEDs monitor the ECG via self-adhesive electrodes applied to the patient’s chest. Rhythm is analyzed by a microprocessor in the defibrillator and if its algorithm detects VF, devices either sound an alarm that a shock is advised, or in completely automatic versions, a defibrillation shock is delivered after an audible warning to stand clear. Specificity rates of the VF detection algorithm approach 100%. Emergency service personnel equipped with AEDs achieve higher resuscitation and survival rates than those equipped with manual defibrillators or no defibrillators at all. This is likely because of the reduced time to first-shock delivery with AEDs. Widespread AED availability in the community has proven to be beneficial in improving survival from prehospital cardiac arrest. In a large public-access defibrillation study, there were significantly more survivors to hospital discharge in scenarios where lay volunteers were trained in AED use and cardiopulmonary resuscitation (CPR; 23%) as opposed to CPR alone (14%).\(^6\) Similar benefit has been demonstrated for AEDs used in schools as well as by police.\(^7,8\) However, public-access AEDs are involved in only a modest fraction of all cardiac arrests, and widespread early use remains a challenge.

### Chest Compression

When defibrillation fails to restore circulation, restoration of blood flow is needed.\(^9\)–\(^11\) Some measure of blood flow is generally produced by chest compression\(^12\) although more advanced strategies are being studied.\(^13\) The standard is manual chest compression where the sternum is depressed at least 2 inches at least 100 times per minute, with half of the time in compression.\(^14\) Because these manual chest compressions can be difficult to do and can cause substantial operator fatigue, mechanical devices are being studied as a way of producing more consistent chest compressions. Current mechanical devices include the LUCAS system\(^15\) and the Load Distributing Band (Autopulse) system.\(^16\) The LUCAS system evolved from studies of chest compression with active compressions and decompressions,\(^17\) whereas the Load Distributing Band system evolved from studies of circumferential compressions with a pneumatic cuff.\(^18\) Both devices are associated with outcomes that are similar to those obtained with manual chest compressions.\(^13,16,19\) In addition, the combination of a manual system that provides active compressions and decompressions, as well as the impedance threshold device,\(^20\) which impedes the flow of air out of the chest during chest decompression, was

### Nonstandard Abbreviations and Acronyms

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AED</td>
<td>automatic external defibrillator</td>
</tr>
<tr>
<td>CPR</td>
<td>cardiopulmonary resuscitation</td>
</tr>
<tr>
<td>PCI</td>
<td>percutaneous intervention</td>
</tr>
<tr>
<td>PEA</td>
<td>pulseless electric activity</td>
</tr>
<tr>
<td>ROS</td>
<td>reactive oxygen species</td>
</tr>
<tr>
<td>SCA</td>
<td>sudden cardiac arrest</td>
</tr>
<tr>
<td>VT</td>
<td>ventricular tachycardia</td>
</tr>
<tr>
<td>VF</td>
<td>ventricular fibrillation</td>
</tr>
</tbody>
</table>
shown to be associated with outcomes that were improved over those obtained with standard chest compressions. In a large randomized trial of conventional manual CPR, however, the impedance threshold device compared with sham did not improve survival. Finally, the amount of ventilation that is required for successful resuscitation remains to be clarified.

Pulseless Electric Activity

At present, there is no single unifying definition for PEA. Moreover, in contrast to the proven therapy of early defibrillation for VF, less is known about effective therapies for PEA. The common denominator is the presence of spontaneous organized cardiac electric activity, in the absence of blood flow sufficient to maintain consciousness, and the absence of rapid spontaneous return of circulation. The latter qualifier excludes transient losses of blood flow, such as vasovagal syncope, that have clinical implications different from true PEA. PEA is thus defined as a syndrome characterized by the absence of a palpable pulse in an unconscious patient with organized electric activity other than ventricular tachyarrhythmia on ECG.

PEA can be classified into 3 groups/stages: norotmensive PEA, pseudo-PEA, and true PEA. Norotmensive PEA occurs in the situation of baseline cardiac contractions and myocardial fiber shortening and typically occurs secondary to an extracardiac problem, such as tension pneumothorax or tamponade. Pseudo-PEA is defined as the situation with weak myocardial contractions that only produce detectable aortic pressures as measured by invasive monitoring or echocardiography. True PEA is total absence of myocardial contractions, which is typically the final stage of PEA that occurs after prolonged exposure to acidosis/hypoxia/increased vagal tone.

The overall Resuscitation Outcomes Consortium survival rate for treated patients with PEA arrests surviving to hospital discharge was ≈8%. This compares with 30.5% for VT/VF arrests. Survival from PEA arrests in public settings was 14.9% and home arrests 7.5%. Similarly low survival rates were reported by the CARES Network. In a study of greater than 50,000 inhospital cardiac arrests from the period between 1999 and 2005, the first documented pulseless rhythm was VT in 3810 (7%), VF in 8718 (17%), PEA in 19262 (37%) and asystole 20129 (39%; 18). In that study, survival to hospital discharge rate was not different between those with first documented VF and VT (37% vs 18). In a retrospective analysis from the Oregon SUDS (Sudden Unexpected Death Study), a lifetime clinical history of syncope was identified as a novel association with PEA and remained a significant determinant of PEA after adjusting for other conditions (odds ratio, 2.64 [1.31–5.32]). The preponderance of syncope among PEA cases was not explained by an increased prevalence of conduction system disease, leading to the interesting possibility that in a subgroup of patients, severe hypotension caused by peripheral vascular failure or a malignant form of vasovagal syncope may account for manifestation with PEA.

Mechanisms and Pathophysiology of PEA

Defining the pathobiology and management of PEA has been limited by the lack of clinically relevant laboratory models. Asphyxia is the traditional experimental method of inducing PEA arrest and this model, in varying forms, has been used since the 1960s. However, asphyxia is not a common clinical cause of out-of-hospital PEA arrest in the adult population. In autopsy studies, ≈50% of cases of PEA may be ascribed to a primary cardiac event. In 1 study, PEA as the initial rhythm was observed in 50% to 60% of cardiac arrests with onsets witnessed by advanced rescuers (paramedics) and was not preceded by a reported respiratory event. Finally, up to one third of patients resuscitated from cardiac arrest caused by PEA undergo a percutaneous intervention for acute coronary occlusion and ST-segment–elevation myocardial infarction, suggesting that PEA may be an initial arrhythmic event resulting from acute ischemia.

In the 1980s PEA after countershock of prolonged, untreated VF was introduced as a PEA model. This model does not replicate primary PEA; it is more similar to PEA after a shock terminating prolonged VF. Observations during resuscitation after postshock PEA have demonstrated evidence of metabolic and electrolyte disturbances that could sustain PEA after defibrillation. Whether these are causes, conditioning influences, or therapeutic targets requires further clarification. A possible role of the parasympathetic nervous system in primary PEA has been indirectly evaluated in an asphyxia model in which surgical or chemical (high-dose atropine) vagotomy was performed after induction of PEA with asphyxia. Return of spontaneous circulation was more likely after surgical vagotomy but high-dose atropine had no beneficial effect. The mechanistic benefit of vagotomy was unclear.

Cellular Mechanisms and Contractile Dysfunction

For some time, acute coronary occlusion has been known to result in a sudden loss of contractile force. The most likely cause is abrupt loss of tissue turgor, also known as the reverse garden hose effect. The mechanism underlying the garden hose effect is uncertain, but may be related to loss of optimum cross-bridge overlap (eg, starling forces) when the erectile effect of the vasculature is abrogated. Because intracellular calcium (Ca++) is critical for regulating myocardial contraction, an alternate hypothesis is that loss of vascular pressure alters vasotropc feedback that modulates triggered Ca entry or myofilament Ca sensitivity. Metabolic consequences of ischemia likely contribute to further contractile dysfunction. This may be of particular importance for PEA after countershock after prolonged VF. It is important to recognize that many of the metabolic changes seen are associated with chronic heart failure as well. Thus, metabolic stress could also contribute to loss of contractility leading to PEA in patients with advanced heart failure.
Inotropic agents, particularly β agonists, have been the mainstay of therapy for PEA, based on considerations of molecular factors involved in contractile function and dysfunction. β-agonists phosphorylate L-type Ca++ channels, ryanodine receptors, the sarcoplasmic reticulum Ca-ATPase regulator phospholamban, and myofilaments to not only increase triggered calcium entry into the cell but also synchronize calcium release from a loaded sarcoplasmic reticulum and improve myofilament Ca-responsiveness. There is, however, a time-dependent loss of contractile function in response to the metabolic stress of acute ischemia. Because the mechanisms for this loss are unknown, additional studies to elucidate these mechanisms are needed to provide a rational basis for future therapies. In addition, whether myofilament Ca-sensitizers, such as levosimendan, or other agents, may be of additional or greater benefit in the setting of PEA has yet to be determined.

Clinical associations between the presence of inflammatory cytokines and sudden cardiac death have been established. In the MERLIN-TIMI (Metabolic Efficiency with Ranolazine for Less Ischemia in Non–ST-Elevation Acute Coronary Syndromes – Thrombolysis in Myocardial Infarction) 36 trial, elevation of cytokines, such as osteoprotegerin, was the best predictor of early sudden death after myocardial infarction.57,58 Furthermore, the proposed benefit of N-3 fatty acids on cardiac mortality post MI and in heart failure settings has also been attributed at least partially to the anti-inflammatory effects of N-3 fatty acids.59

The effect of production of cytokines/cardiokines, such as tumor necrosis factor and the interleukin family of cytokines, may acutely depress cardiac function. This has been attributed to the effect on phosphatidylinositol 3 kinase isoforms and lipid signaling intermediates, such as sphingosine-1, which may directly interfere with Ca signaling.59 More recently, there has also been data to suggest that high mobility group box 1 or alarmin family of signals may also directly depress cardiac function and Ca kinetics.51 However, this effect may be partially ameliorated through phosphatidylinositol 3 kinase γ blockade, suggesting possible avenues for host protection.

Although there has been a significant interest in the role of relaxin, a naturally occurring hormone that increases in women during pregnancy, in acute heart failure, its mechanisms of action are not well known.52 In an animal model of acute ischemic arrest, relaxin was able to significantly reduce the adverse outcomes of asystole, ventricular tachyarrhythmias, or bradyarrhythmic arrests, possibly through anti-inflammatory effects by inhibiting mast cell activation.53

Further research is needed to weigh the role of immune modulation in the PEA pathway, especially in the context of underlying comorbidities such as diabetes mellitus, heart failure, and other proinflammatory disease states. An intriguing hypothesis, based on the possibility that β-blockers protect against the expression of VT/VF during ischemia, is that inflammatory signals may allow PEA to emerge by default.

Changing Patterns of SCA
Thirty years ago, >70% of the initial electrocardiograms recorded during cardiac arrests showed VF or pulseless VT.23 Recent data from several large population cohorts, covering >40,000 patients, demonstrate proportions of initial VT/VF in the range of 20% to 25%.54,55

In a study from Seattle, all out-of-hospital cardiac arrests were studied in the years from 1979 to 2000. The incidence of VF as the first documented rhythm changed over the 20-year study period from 61% of cardiac arrests to 41% of cardiac arrests. The incidence of asystole as the first recorded rhythm went from 21% to 31% during that same time period and for PEA, the change was from 17% to 28%.56

This striking decline in the frequency of VT/VF, and the relative and possibly absolute increase in PEA and asystole as the initial rhythm, may be because of many interacting environmental, clinical, pharmacological, or strategic interventional factors. At least one of these may be analyzed in the context of the location of cardiac arrests. From Resuscitation Outcomes Consortium data based on 12930 total arrests stratified by location, VT/VF occurred in 22% of 9564 arrests occurring in homes, 13% of 1324 occurring in nursing homes or residence facilities, and 51% of 2042 arrests occurring in a public location.57 Thus, one might conclude that for arrests occurring in public locations and likely benefiting from rapid recognition and management, the incidence of VT/VF is not much lower than 30 years ago. However, patients who have cardiac arrests in the home, or in the nursing home, where the incidence of VT/VF is reduced, may be older, have more severe chronic conditions, or may be subject to delays in recognition and initial responses. The decline in VT/VF may also be contributed to by the increase in implantable cardioverter defibrillators in patients with systolic heart failure and the increasing use of aggressive pharmacological management of heart failure, particularly β blockers, which may suppress VT/VF and result in an increase in cardiac arrest related to both PEA and asystole.28 However, these potential determinants of the increasing burden of PEA need further investigation.

Ischemia and Reperfusion/Reperfusion Injury
The biological processes that determine whether a heart will return to normal after an episode of ischemia versus fail to recover remain unknown. Of primary interest to the clinician is the controversial notion of reperfusion injury that occurs during the metabolic phase of cardiac arrest with prolonged cardiac arrest.28 Reperfusion injury denotes a potentially avoidable pathological process wherein potentially viable cells die not entirely because of the cellular derangements of ischemia.60-62 Death occurs during the reperfusion phase because of the combination of the ischemia-induced metabolic alterations plus the conditions of reperfusion specific to the sudden reintroduction of normal levels of oxygen and other substrates. Underlying the concept of reperfusion injury were studies from the 1970s and 1980s that observed 3 paradoxes in cells and in organs.63

The initial observation of a calcium paradox followed the observation that if normal levels of calcium were rapidly reintroduced to cardiac cells, which are routinely grown in calcium-free media, the cells would rapidly die on re-exposure to the previously normal levels of calcium.64,65 Similar studies demonstrated cell death after normalization of pH after cells were adapted to low pH conditions, as well as accelerated cell death on reoxygenation (usually with room air 150 torr oxygen) of cells adapted to lowered oxygen levels.66 It is now well accepted that cells grown in culture demonstrate the ability
Reperfusion Injury Seems to be Critically Time Dependent

Similar to the time dependency of the metabolic phase described by Weisfeldt’s 3-phase model, there is an important time dependency for reperfusion injury. It is clear that shorter periods of ischemia do not have any reperfusion injury at all. Indeed the opposite is seen because short intervals of complete ischemia can produce ischemic preconditioning, a state of protection and decreased injury. As opposed to preconditioning protection, the concept of reperfusion injury is that after some more prolonged ischemic period, the cells cross a threshold of metabolic derangement. Only after this threshold is passed, cells will demonstrate reperfusion injury. This implies that before this critical threshold time is reached, immediate reperfusion is the best treatment approach to shorter periods of ischemia. However, after some lengthening interval of prolonged ischemia, there comes a time point at which the immediate reperfusion of normal oxygenated blood into the ischemic organ produces additional injury and death than some alternative approach for controlled reperfusion such as the use of an antireperfusion injury cocktail or cooling. While still controversial, there is much data from cellular models, animal models, and even limited human studies that this notion of reperfusion injury affects humans under conditions of ischemia and is relevant to clinicians under some situations of ischemic injury.

Mechanisms of Reperfusion Injury in the Metabolic Phase of Prolonged Cardiac Arrest

The alterations during ischemia lay the foundation for subsequent reperfusion injury. With ischemia and diminished availability of oxygen, there is a rapid reduction of ATP production and ATP levels. Without oxygen to be used as a terminal electron acceptor within the mitochondria, there is a rapid intracellular electron leakage that results in the normal electron-rich metabolites that lack the normal path of mitochondrial oxidation products. The accumulation of the normal electron acceptor within the mitochondria matrix and endoplasmic reticulum is reduced. Loss of osmotic control and cell swelling occurs as the ionic gradients are lost.

As ischemia continues, there are increasing derangements of the intermediates of central metabolisms are described in a recent metabolomics survey of the rodent heart after 30 minutes of cardiac arrest. Significant increases occur in short-chain acyl carnitines (valeryl carnitine, hydroxybutyryl carnitine, 2-methylbutyrylcarnitine, and propionylcarnitine) and 3-hydroxybutyryl CoA. These findings suggest that accumulation of branched-chain amino acids represents incomplete mitochondrial oxidation products. The accumulation of the CoAs and carnitines is likely because of the lack of oxygen to support operation of the mitochondrial oxidative phosphorylation. In addition, the organic osmolytes such as mannitol, ribitol, and sorbitol were seen to be increased, likely this is the response to the hyperosmolality caused by the increased concentrations of inorganic ions. As expected with ischemia, carbohydrate metabolites were substantially decreased in the heart tissue, particularly metabolites in the glycolysis pathway (glucose, glucose-6-phosphate, and fructose-6-phosphate), the pentose phosphate pathway (sedoheptulose 7-phosphate), and their precursors (mannose-6-phosphate and glucose-1-phosphate). Maltotriose, maltotetraose, maltopentaose, and maltohexaose (oligomeric forms of glucose) were also substantially decreased as the heart continues to consume and deplete carbohydrates for energy generation during ischemia.

It is into this milieu of the deranged metabolism that reperfusion and reoxygenation brings in a sudden surge of oxygen and new substrates. A sudden and large burst of ROS can be detected within the heart (and other organs) on reoxygenation. Although it is generally acknowledged that this oxidative stress is a major factor in the cause of reperfusion injury, considerable debate centers around which sources of ROS are most important and what are the primary cellular and organ targets for oxidative damage. Possible sources of ROS generation include the cytosolic nicotinamide adenine dinucleotide phosphate-oxidase–linked NOX enzymes, the inflammatory process, xanthine oxidase, and mitochondrial dysfunction. Cellular targets include nuclear DNA damage, cytosolic proteins, and mitochondrial oxidative phosphorylation and mitochondrial DNA. An amplifying cascade of oxidative damage is set into motion wherein ROS produces damage, which then produces more ROS. Major contenders for the organs most sensitive to reperfusion include the heart and brain.

Mitochondria Appear at the Heart of Reperfusion Injury

Mitochondria act as a nexus for reperfusion injury pathways. The mitochondria are one of the most important sources of ROS within individual cells and mitochondrial oxidative phosphorylation and the tricarboxylic acid cycle enzymes are acutely sensitive to ROS damage. Therefore, the mitochondria may be important in both the generation of ROS and as a target for the functional disruption of the cell by reperfusion injury stimulated ROS. If true, one would predict that the outcome of reperfusion after cardiac arrest should be made worse if either the endogenous rate of mitochondrial ROS were increased or if the mitochondrial antioxidant...
defenses were impaired. There is much laboratory evidence to support both of these pathways as important during reperfusion. Consistent with this is the observation that the brain and the heart are the organs most reliant on mitochondrial bioenergetics.

**Calcium Control Mechanisms**

In addition, alterations because of dysfunctional calcium control also amplify the injuries of ischemia and reperfusion. Elevations of cytosolic calcium occur rapidly as the high concentrations of sequestered calcium in the mitochondrial and endoplasmic reticulum begin to equilibrate because of the loss of energy to maintain the gradient and alterations in membrane channels and receptors. Not only does this begin to uncouple mitochondrial ATP generation, but widespread activation occurs of enzymes such as calpains and other proteases, nitric oxide synthase, calcineurin, and endonucleases that produce proteolysis and widespread injury by additional pathways.

**Advanced Resuscitation Strategies: Combining Emergency Cardiopulmonary Bypass Plus Metabolic Cocktails Targeted Toward Preventing Reperfusion Injury**

Putting the basic science of reperfusion injury biology together with the need for better circulation of blood suggests a future direction for the treatment of the metabolic phase or intractable cardiac arrest. These new approaches are likely to work well in synergy with our proven therapies, such as early CPR, defibrillation, and percutaneous coronary intervention (PCI). To treat the complex metabolic dysfunction and high lethality of prolonged cardiac arrest, most experts are predicting an expansion of the use of invasive cardiopulmonary bypass in concert with drugs (likely several drugs combined together as a cocktail). The use of emergency cardiopulmonary bypass with the ability to produce nearly normal levels of blood flow is a logical extension of CPR but has only recently been shown to be practical for selected patients in emergency situations. Emergency cardiopulmonary bypass requires the placement of large cannula in a major artery and a major vein (typically femoral artery and vein). The life-saving effect of this approach has been reported primarily from Japan, where Nagao and Sakamoto and other colleagues have developed a growing network for the rapid deployment of emergency cardiopulmonary bypass (ECPB) in the emergency department. Now available to cardiac arrest victims in >30 cardiac arrest centers across Japan, these emergency facilities have developed the art of rapid emergency cannulation, full circulatory support, and rapid PCI. They achieve full arterial and venous cannulations and blood flow typically within 15 minutes after the arrival of an arrested patient. The survival rates are likewise impressive given that all these patients were unresponsive to prehospital ACLS and remained in refractory cardiac arrest in the emergency department despite 10 minutes of full ACLS efforts. Although the survival rate of these patients would be predicted to be <1% in most US emergency departments, the Japanese experience would suggest that survival rates with good neurological function of >15% are possible in these selected patients. Another advantage of using full circulatory support is that it also allows for rapid PCI treatment of an occluded coronary artery. Rapid PCI is a vital component of the use of ECPB to prevent myocardial necrosis and the long-term sequela of coronary occlusion. It is possible that the most significant value of emergency cardiopulmonary bypass will be when it is coupled with a metabolic strategy against reperfusion injury (ie, an antireperfusion injury cocktail). The clearest demonstration of this potential value comes from the experimental laboratory of Buckberg and colleagues, who reported results of swine experiments with a lethal period of brain ischemia. They subjected swine to 30 minutes of complete brain ischemia, a time period that is universally devastating. The experimental group received an antireperfusion injury cocktail that included hypocalcemia, hypermagnesemia, alkalosis, hyperosmolarity, and blood conditioned via a white blood cell filter. This cocktail was circulated around within the vessels of the brain for 20 minutes before reestablishment of recirculation of normal blood. The control group received normal blood reperfusion as would be the practice now. All of the control animals as expected died with extensive brain injuries. However, the experimental group all survived, with good neurological function in the majority of animals. This study is a dramatic demonstration of the potential of the ECPB plus cocktail approach. Bartos et al and Debaty et al have taken a similar approach and are likewise now able to routinely resuscitate swine from 15- to 20-minute periods of cardiac arrest, a resuscitation feat almost never before reported in the literature. They are using a bundle of techniques including manual CPR techniques to maximize blood flow including vigorous chest compression, abdominal binding, drugs targeted to mitochondria and membrane integrity, and using the inspiratory threshold device. These advanced CPR techniques produce much higher blood flow than standard CPR. But improving blood flow alone is not sufficient to produce survival from these longer periods of cardiac arrest. They have worked with cocktails that include NO, isoflurane, and poloxamers. What they report from these studies supports the notion that the combination of improved blood flow along with metabolic therapies will produce survival from what was a previously uniformly fatal period of cardiac arrest. It is possible that the future of resuscitation will involve this approach because it is the most currently viable method for the treatment of the patients in the metabolic phase of cardiac arrest.

A recent article using ECPB to salvage patients with both in-hospital and out-of-hospital cardiac arrest following refractory cardiac arrest conducted in Australia puts many of these advanced resuscitation themes together. They combined many of the modalities we have discussed, sequentially delivering the following: (1) a mechanical CPR chest compression device due to long arrest times, (2) starting intra-arrest cooling with ice-cold saline delivered while the patients were still in refractory cardiac arrest, (3) rapid cannulation in the hospital with initiation of ECPB, and (4) rapid PCI with advanced critical care. Patients were only eligible for the study when they had suffered 30 minutes of refractory cardiac arrest with attempted resuscitation using standard ACLS measures. This is an important time point because the health care providers have the option to discontinue efforts and pronounce...
the patient dead after these 30 minutes. However, rather than pronouncing these patients dead, the patients were enrolled in the study using this advanced resuscitation protocol if they met inclusion criteria of initial rhythm of VF, had CPR started within 10 minutes of collapse, were aged between 18 to 65, and when a mechanical device was available. While this was a small feasibility study, of the 26 patients with refractory cardiac arrest, 14 (54%) were discharged from the hospital with good neurological function. Both in-hospital survival (9/15) and out of hospital survival (5/11) were surprisingly high in these selected patients with the combined mechanical CPR, intra-arrest cooling, ECPB and PCI approach.

Collectively, these data tell us that although early cardiac arrest can be treated successfully with current therapies, new therapies will be required to surmount the metabolic phase of cardiac arrest. However, the data also increasingly suggest that this metabolic phase need not be universally fatal. With new research initiatives and research funding, markedly improved survival rates could become the norm within a decade. The best hope to achieve this vision is to couple current proven therapies such as early defibrillation and early CPR with evolving strategies derived from investigations such as the rapid deployment of emergency cardiopulmonary bypass and PCI in conjunction with a metabolic strategy targeted at avoiding reperfusion injury, restoring normal mitochondrial function, and returning tissues to metabolic homeostasis.

Sources of Funding
The authors are funded by National Institutes of Health.

Disclosures
None.

References


42. Hess ML, Manson NH. Molecular oxygen: friend and foe. The role of the oxygen free radical system in the calcium paradox, the oxygen paradox and ischemia-reperfusion injury. J Mol Cell Cardiol. 1984;16:969–985.


Cardiac Arrest: Resuscitation and Reperfusion 2049


Cardiac Arrest: Resuscitation and Reperfusion
Kaustubha D. Patil, Henry R. Halperin and Lance B. Becker

Circ Res. 2015;116:2041-2049
doi: 10.1161/CIRCRESAHA.116.304495
Circulation Research is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2015 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7330. Online ISSN: 1524-4571

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circres.ahajournals.org/content/116/12/2041

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation Research can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation Research is online at:
http://circres.ahajournals.org//subscriptions/